FLSM
ARVN icon

Frazier Life Sciences Management’s Arvinas ARVN Stock Holding History

Frazier Life Sciences Management’s Portfolio ARVN Stock Details ARVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-285,331
Closed -$5.47M – 49
2024
Q4 		$5.47M Hold
285,331
– – 0.23% 46
2024
Q3 		$7.03M Hold
285,331
– – 0.28% 46
2024
Q2 		$7.6M Hold
285,331
– – 0.36% 41
2024
Q1 		$11.8M Hold
285,331
– – 0.5% 40
2023
Q4 		$11.7M Hold
285,331
– – 0.63% 38
2023
Q3 		$5.6M Hold
285,331
– – 0.37% 42
2023
Q2 		$7.08M Hold
285,331
– – 0.42% 37
2023
Q1 		$7.8M Hold
285,331
– – 0.56% 34
2022
Q4 		$9.76M Hold
285,331
– – 0.61% 33
2022
Q3 		$12.7M Hold
285,331
– – 0.98% 25
2022
Q2 		$12M Buy
285,331
+15,000
+6% +$753K 1.13% 23
2022
Q1 		$18.2M Buy
+270,331
New +$18.4M 1.55% 20

Other funds holding ARVN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return